Vladimir Coric Family Trust

Vladimir Coric Family Trust

The Vladimir Coric Family Trust is the personal investment vehicle of Dr. Vladimir Coric, a psychiatrist-turned-biotech executive who co-founded and led Biohaven Pharmaceuticals from clinical-stage startup to one of the most consequential central nervous system drug launches of the past decade. The firm's wealth originates entirely from Biohaven's sale to Pfizer, which closed in October 2022 and delivered approximately $11.6 billion in total consideration to shareholders. Dr. Coric, who served as Biohaven's CEO and Chairman, retained a significant equity stake throughout the company's public-market tenure. The trust's investment strategy reflects its single-concentration origins — a portfolio shaped by one of the largest biopharma exits in recent memory. Public filings and real-estate records point to a mix of diversified public equities, fixed-income holdings, and direct real property acquisitions across the Connecticut and Massachusetts corridor. The trust has demonstrated no formal venture-capital platform or fund commitments, operating instead through separately managed accounts and direct asset purchases. Known real-asset positions include residential and mixed-use properties in the greater New Haven area, where Biohaven maintained its headquarters. Team size and total deployment remain undisclosed. The trust maintains footprints in the three locations associated with Biohaven's operational history — Waltham, Massachusetts; Woodbridge, Connecticut; and New Haven, Connecticut — suggesting a lean family-office structure likely supported by external wealth managers and a small internal staff. Dr. Coric continues to serve on the board of Biohaven Ltd., the post-split entity that retained the company's non-migraine neuroscience pipeline, which keeps the family's financial interests tethered to the ongoing development of troriluzole and other late-stage assets. Structurally, the trust operates with a mandate that looks more like a concentrated post-liquidity portfolio than a diversified institutional family office. There is no evidence of a foundation, donor-advised fund, or philanthropic vehicle formally separated from the trust's investment activities. Succession and governance details are not public, and the trust does not appear to take outside co-investors, positioning it as a closed, single-decision-maker vehicle organized around one individual's scientific and financial legacy.